The Progressive Corporation (PGR)

Progressive closed the most recent session up 0.77% at $233.53, sitting 86% of the way up its 52-week range and 3.11% below the high of $241.02. The move comes after a quarter in which the stock fell 4.23% in the first session following its October 13, 2026 report, even though adjusted EPS of $4.60 beat the $4.41 estimate by 4.31%. The stock trades at a trailing P/E of 11.78, well below the sector median of 16.5, and it is 6.41% above its 50-day SMA and 11.04% above its 200-day SMA. For investors the key question is whether an insurer priced at a steep discount can keep growing earnings while revenue growth lags the sector.

Progressive reported adjusted EPS of $4.60 on October 13, 2026, against an analyst estimate of $4.41, a beat of 4.31%. The shares nonetheless fell 4.23% in the first trading session after the report. That reaction is the more useful signal for investors. It shows that the market is not rewarding a beat on its own in this case. The earnings record is still strong: five of the last seven reports beat the estimate, and the stock rose in the first session after four of the seven reports. The one beat that was followed by a lower price was the October 2026 report, and the two misses came with a 19.80% shortfall in October 2025.

At a trailing P/E of 11.78, the stock is priced 28.6% below the sector median of 16.5. The price-to-sales ratio of 1.48 is 61.1% below the sector median of 3.8. Return on equity of 33.24% is well above the sector median of 13.8%, and debt-to-equity is 0.24. Those figures explain why the stock screens as cheap. They also show a business with high profitability and low leverage. The gap is widest on revenue, where growth of 3.00% in the latest quarter, year on year, trails the sector median of 11.7% by 8.7 percentage points. The discount is therefore tied to slower top-line growth.

Insiders sold $72.1M of stock over the last 18 months across 50 sales, with no open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they carry less weight than purchases would. On the sell side, Evercore ISI Group kept its In-Line rating on November 3, 2026, Wells Fargo kept its Underweight rating on October 15, 2026, and Keefe, Bruyette & Woods kept its Outperform rating on the same day. Barclays kept its Overweight rating on October 7, 2026, and JP Morgan kept its Neutral rating on October 5, 2026. Eight of the 25 analysts rated the stock buy three months ago, the same count as today.

The base case is that the stock keeps trading in the upper part of its range while the trend holds, provided the price stays above the 20-day EMA and the 50-day SMA. Momentum is in the bullish zone with the RSI at 60.4 and the MACD line positive, which supports that case. Analysts are split: 8 of 25 rate the stock buy, 15 hold and 2 sell, and the median 12-month target of $233.00 sits almost exactly at the price. The range of targets, from $196.00 to $262.00, shows how far opinions diverge. The main risk is fundamental. Analysts expect revenue to grow 4.7% this fiscal year, but expect EPS to shrink 12.0% next fiscal year, so a weaker profit outlook could challenge the valuation discount. A break below the 50-day SMA would weaken the trend case, while a move above the 52-week high would open new ground.

Support sits at the 20-day EMA of $227.41, the nearest level below the price. Below it, the 50-day SMA at $219.47 is the next floor, followed by the 200-day SMA at $210.32, which has been a trend line for the longer run. The 52-week low of $189.20 is the deepest reference point below the price. Resistance sits at the 52-week high of $241.02, the nearest level above the price and the level a rise would meet first.